Xencor (XNCR) Non Operating Income (2013 - 2026)
Xencor (XNCR) posted quarterly Non Operating Income of -$50.8 million for Q1 2026, down 899.09% year-over-year from $6.4 million in Q1 2025, and down 202.86% quarter-over-quarter from $49.4 million in Q4 2025.
Analysis
Xencor (XNCR) Non Operating Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Non Operating Income for 14 consecutive years, with -$50.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 899.09% year-over-year to -$50.8 million; the TTM figure through Mar 2026 stood at $42.2 million (up 200.08% YoY), while the FY2025 annual figure was $87.9 million, up 255.48% from the prior year.
- Non Operating Income slipped to -$50.8 million in Q1 2026 per XNCR's latest filing, from $49.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $49.4 million in Q4 2025 and bottomed at -$50.8 million in Q1 2026.
- Historically, Non Operating Income has averaged $1.3 million across 5 years, with a median of -$19000.0 in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 502.07% — and 2024, when it tumbled 102284.21%.
- Xencor's Non Operating Income stood at $30.1 million in 2022, then plunged by 46.63% to $16.1 million in 2023, then sank by 295.26% to -$31.4 million in 2024, then jumped by 257.18% to $49.4 million in 2025, then tumbled by 202.86% to -$50.8 million in 2026.
- Business Quant data shows XNCR's Non Operating Income at -$50.8 million in Q1 2026, $49.4 million in Q4 2025, and $41.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 15.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.15 Mn |
| Mar 31, 2026 | -50.77 Mn |
| Dec 31, 2025 | 49.36 Mn |
| Sep 30, 2025 | 41.49 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | -5.08 Mn |
| Dec 31, 2024 | -31.41 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | -13.41 Mn |
| Mar 31, 2024 | -19.45 Mn |
| Dec 31, 2023 | 16.08 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 30.14 Mn |
| Sep 30, 2022 | 6.68 Mn |
| Jun 30, 2022 | -5.98 Mn |
| Mar 31, 2022 | -2.87 Mn |
| Dec 31, 2021 | -18.59 Mn |
| Sep 30, 2021 | 1.11 Mn |